CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 65 enrolled
Drug / intervention
BI 6727drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02273388
NCT02273388Phase 1Completed
CompareCT.gov

An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

Boehringer Ingelheim·interventional·Posted Oct 24, 2014·Updated Oct 3, 2023

In Brief

A Phase 1 clinical trial evaluating BI 6727 for Neoplasms. Completed, enrolled 65 participants across 2 sites.

Detailed Summary

The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events. Secondary objectives are the collection of overall safety and antitumour efficacy data and the determination of the pharmacokinetic profile of BI 6727.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesBelgium
Collaborators--

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 24, 2014
Enrollment StartNov 4, 2005
Primary CompletionJan 19, 2009
Study CompletionApr 6, 2021
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.7 years ago

Interventions

BI 6727drug

BI 6727